A 5-Year, Multicenter, Open-Label, Safety Study of Adjunctive LatanoprostTherapy for Glaucoma

Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open‐angle glaucoma and ocular hypertension: 24‐month results of a randomized, double‐masked phase III study

“…Amongst PG naı¨ve patients in the present study, increased iris pigmentation at 24 months was observed in 28.0% of latanoprost-treated eyes and 26.1% of tafluprost-treated eyes. These values are similar to the rates observed in the study by Alm et al where 31.3% of patients experienced increased iris pigmentation at 24 months (Alm et al 2004).…”

“…These values are similar to the rates observed in the study by Alm et al. where 31.3% of patients experienced increased iris pigmentation at 24 months (Alm et al. 2004).…”

Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open‐angle glaucoma and ocular hypertension: 24‐month results of a randomized, double‐masked phase III study

“…Amongst PG naı¨ve patients in the present study, increased iris pigmentation at 24 months was observed in 28.0% of latanoprost-treated eyes and 26.1% of tafluprost-treated eyes. These values are similar to the rates observed in the study by Alm et al where 31.3% of patients experienced increased iris pigmentation at 24 months (Alm et al 2004).…”

“…These values are similar to the rates observed in the study by Alm et al. where 31.3% of patients experienced increased iris pigmentation at 24 months (Alm et al. 2004).…”

A randomized, 36‐month, post‐marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non‐prostaglandin therapy in patients with glaucoma or ocular hypertension

“…With regard to safety, latanoprost monotherapy was well tolerated with few reported serious adverse events. These findings are similar to those of a 5‐year study (Alm et al. 2004) of latanoprost as adjunctive therapy and those of a 5‐year study (Goldberg et al.…”

“…Non-PG, non-prostaglandin. These findings are similar to those of a 5-year study (Alm et al 2004) of latanoprost as adjunctive therapy and those of a 5-year study (Goldberg et al 2008) comparing outcomes in patients treated with latanoprost versus any other commercially available medication. The authors of both studies concluded that latanoprost is safe and well tolerated for the longterm treatment of patients with open-angle glaucoma.…”

A 5-year, Randomized, Open-Label Safety Study of Latanoprost and Usual Care in Patients with Open-Angle Glaucoma or Ocular Hypertension

“…Because macular edema and iris/uveitis were initially considered putative effects of prostaglandin agonists, it is conceivable that in this open-label study in which the study treatment administered to individual patients was unmasked by design at least some participating clinicians may have been biased towards attributing a causal rela-tionship with latanoprost more frequently than with other comparative treatments in the usual care group. The presence of increased iris pigmentation did not affect the safety profile of latanoprost, confirming results of a previous 5-year, multicenter, open-label, safety study (23). Serious adverse drug reactions were rare among those in the total latanoprost population, reported in 21/4638 (0.45%) patients of whom 19 were receiving latanoprost at the time of the reaction.…”

Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open‐angle glaucoma and ocular hypertension: 24‐month results of a randomized, double‐masked phase III study

“…Amongst PG naı¨ve patients in the present study, increased iris pigmentation at 24 months was observed in 28.0% of latanoprost-treated eyes and 26.1% of tafluprost-treated eyes. These values are similar to the rates observed in the study by Alm et al where 31.3% of patients experienced increased iris pigmentation at 24 months (Alm et al 2004).…”

“…These values are similar to the rates observed in the study by Alm et al. where 31.3% of patients experienced increased iris pigmentation at 24 months (Alm et al. 2004).…”

A randomized, 36‐month, post‐marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non‐prostaglandin therapy in patients with glaucoma or ocular hypertension

“…With regard to safety, latanoprost monotherapy was well tolerated with few reported serious adverse events. These findings are similar to those of a 5‐year study (Alm et al. 2004) of latanoprost as adjunctive therapy and those of a 5‐year study (Goldberg et al.…”

“…Non-PG, non-prostaglandin. These findings are similar to those of a 5-year study (Alm et al 2004) of latanoprost as adjunctive therapy and those of a 5-year study (Goldberg et al 2008) comparing outcomes in patients treated with latanoprost versus any other commercially available medication. The authors of both studies concluded that latanoprost is safe and well tolerated for the longterm treatment of patients with open-angle glaucoma.…”

A 5-year, Randomized, Open-Label Safety Study of Latanoprost and Usual Care in Patients with Open-Angle Glaucoma or Ocular Hypertension

“…Because macular edema and iris/uveitis were initially considered putative effects of prostaglandin agonists, it is conceivable that in this open-label study in which the study treatment administered to individual patients was unmasked by design at least some participating clinicians may have been biased towards attributing a causal rela-tionship with latanoprost more frequently than with other comparative treatments in the usual care group. The presence of increased iris pigmentation did not affect the safety profile of latanoprost, confirming results of a previous 5-year, multicenter, open-label, safety study (23). Serious adverse drug reactions were rare among those in the total latanoprost population, reported in 21/4638 (0.45%) patients of whom 19 were receiving latanoprost at the time of the reaction.…”

Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open‐angle glaucoma and ocular hypertension: 24‐month results of a randomized, double‐masked phase III study

“…Amongst PG naı¨ve patients in the present study, increased iris pigmentation at 24 months was observed in 28.0% of latanoprost-treated eyes and 26.1% of tafluprost-treated eyes. These values are similar to the rates observed in the study by Alm et al where 31.3% of patients experienced increased iris pigmentation at 24 months (Alm et al 2004).…”

“…These values are similar to the rates observed in the study by Alm et al. where 31.3% of patients experienced increased iris pigmentation at 24 months (Alm et al. 2004).…”

A randomized, 36‐month, post‐marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non‐prostaglandin therapy in patients with glaucoma or ocular hypertension

“…With regard to safety, latanoprost monotherapy was well tolerated with few reported serious adverse events. These findings are similar to those of a 5‐year study (Alm et al. 2004) of latanoprost as adjunctive therapy and those of a 5‐year study (Goldberg et al.…”

“…Non-PG, non-prostaglandin. These findings are similar to those of a 5-year study (Alm et al 2004) of latanoprost as adjunctive therapy and those of a 5-year study (Goldberg et al 2008) comparing outcomes in patients treated with latanoprost versus any other commercially available medication. The authors of both studies concluded that latanoprost is safe and well tolerated for the longterm treatment of patients with open-angle glaucoma.…”

A 5-year, Randomized, Open-Label Safety Study of Latanoprost and Usual Care in Patients with Open-Angle Glaucoma or Ocular Hypertension

“…Because macular edema and iris/uveitis were initially considered putative effects of prostaglandin agonists, it is conceivable that in this open-label study in which the study treatment administered to individual patients was unmasked by design at least some participating clinicians may have been biased towards attributing a causal rela-tionship with latanoprost more frequently than with other comparative treatments in the usual care group. The presence of increased iris pigmentation did not affect the safety profile of latanoprost, confirming results of a previous 5-year, multicenter, open-label, safety study (23). Serious adverse drug reactions were rare among those in the total latanoprost population, reported in 21/4638 (0.45%) patients of whom 19 were receiving latanoprost at the time of the reaction.…”